ReviewFrontiers in oncology2022

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.

Valeria Ferla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.